Logo     Print Page  Close Window


SEC Filings


10-Q
FIBROCELL SCIENCE, INC. filed this Form 10-Q on 08/09/2018
Entire Document
 

Fibrocell Science, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
($ in thousands, except share and per share data)

 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2018
 
2017
 
2018
 
2017
Total revenues
$

 
$

 
$

 
$

 
 
 
 
 
 
 
 
Total cost of revenue

 

 

 

 
 
 
 
 
 
 
 
Gross profit (loss)

 

 

 

 
 
 
 
 
 
 
 
Research and development expense
1,415

 
1,679

 
3,060

 
3,143

Research and development expense - related party (see Note 8)
106

 
1,678

 
(197
)
 
3,187

Selling, general and administrative expense
1,556

 
1,670

 
3,195

 
3,151

Operating loss
(3,077
)
 
(5,027
)
 
(6,058
)
 
(9,481
)
Other income (expense):
 
 
 
 
 
 
 
Warrant revaluation income (expense)
91

 
(9,677
)
 
326

 
(9,723
)
Derivative revaluation income
242

 
853

 
179

 
541

Interest expense
(191
)
 
(185
)
 
(381
)
 
(368
)
Other income, net
41

 
18

 
139

 
6

Loss before income taxes
(2,894
)
 
(14,018
)
 
(5,795
)
 
(19,025
)
Income taxes

 

 

 

Net loss
(2,894
)
 
(14,018
)
 
(5,795
)
 
(19,025
)
Dividend paid in-kind to preferred stockholders
(83
)
 
(80
)
 
(165
)
 
(100
)
Deemed dividend on preferred stock (see Note 10)
(126
)
 
(136
)
 
(247
)
 
(3,870
)
Net loss attributable to common stockholders
$
(3,103
)
 
$
(14,234
)
 
$
(6,207
)
 
$
(22,995
)
 
 
 
 
 
 
 
 
Per Share Information:
 
 
 
 
 
 
 
Net loss:
 
 
 
 
 
 
 
     Basic
$
(0.49
)
 
$
(4.84
)
 
$
(1.03
)
 
$
(7.82
)
     Diluted
$
(0.49
)
 
$
(4.84
)
 
$
(1.03
)
 
$
(7.82
)
Weighted average number of common shares outstanding:
 
 
 
 
 
 
 
     Basic
6,376,048

 
2,940,899

 
6,026,454

 
2,940,763

     Diluted
6,376,048

 
2,940,899

 
6,026,454

 
2,940,763



The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.



6